Effect of weekly or daily dosing regimen of Gefitinib in mouse models of lung cancer

Gefitinib showed response in phase II clinical trials and with better clinical response in lung cancer with activating mutations in the tyrosine kinase domain of the EGFR. Questions of toxicity and potential dosing regimens impede the use in a prevention setting. This study will provide scientific e...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Zhang, Qi, Li, Ruichao, Chen, Xu, Lee, Sang Beom, Pan, Jing, Xiong, Donghai, Hu, Jiaqi, Miller, Mark Steven, Szabo, Eva, Lubet, Ronald A., Wang, Yian, You, Ming
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2017
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5641144/
https://ncbi.nlm.nih.gov/pubmed/29069801
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.19785
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires